Expression of angiopoietin-like 4 fibrinogen-like domain (cANGPTL4) increases risk of brain metastases in women with breast cancer

Background: Brain metastases challenge daily clinical practice, and the mechanisms by which cancer cells cross the blood-brain barrier remain largely undeciphered. Angiopoietin-like 4 (ANGPTL4) proteolytic fragments have controversial biological effects on endothelium permeability. Here, we studied the link between ANGPTL4 and the risk of brain metastasis in cancer patients. Materials and Methods: From June 2015 to June 2016, serum samples from 113 cancer patients were prospectively collected, and ANGPTL4 concentrations were assessed. Using a murine model of brain metastases, we investigated the roles of nANGPTL4 and cANGPTL4, the two cleaved fragments of ANGPTL4, in the occurrence of brain metastases. Results: An ANGPTL4 serum concentration over 0.1 ng/mL was associated with decreased overall-survival. Multivariate analyses found that only breast cancer brain metastases were significantly associated with elevated ANGPTL4 serum concentrations. 4T1 murine breast cancer cells were transfected with either nANGPTL4- or cANGPTL4-encoding cDNAs. Compared to mice injected with wild-type 4T1 cells, mice injected with nANGPTL4 cells had shorter median survival (p < 0.05), while mice injected with cANGPTL4 had longer survival (p < 0.01). On tissue sections, compared to wild-type mice, mice injected with nANGPTL4 cells had significantly larger surface areas of lung metastases (p < 0.01), and mice injected with cANGPTL4 had significantly larger surface areas of brain metastases (p < 0.01). Conclusions: In this study, we showed that a higher expression of Angiopoietin-like 4 Fibrinogen-Like Domain (cANGPTL4) was associated with an increased risk of brain metastases in women with breast cancer.

[1]  A. Janin,et al.  How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases , 2019, International journal of molecular sciences.

[2]  K. Krzemiński,et al.  Effect of mountain ultra-marathon running on plasma angiopoietin-like protein 4 and lipid profile in healthy trained men , 2019, European Journal of Applied Physiology.

[3]  S. Murphy,et al.  A TAZ–ANGPTL4–NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer , 2019, Molecular Cancer Research.

[4]  Yubo Fan,et al.  Interaction of tumor cells and astrocytes promotes breast cancer brain metastases through TGF-β2/ANGPTL4 axes , 2019, npj Precision Oncology.

[5]  A. Sodhi,et al.  Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema. , 2019, The Journal of clinical investigation.

[6]  B. Deng,et al.  High Expression of Angiopoietin-like Protein 4 in Advanced Colorectal Cancer and its Association with Regulatory T Cells and M2 Macrophages , 2019, Pathology & Oncology Research.

[7]  Pengcheng Zhu,et al.  Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia , 2019, mBio.

[8]  D. Hoon,et al.  ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis. , 2017, Oncotarget.

[9]  Noha M Shafik,et al.  Significance of Tissue Expression and Serum Levels of Angiopoietin-like Protein 4 in Breast Cancer Progression: Link to NF-κB /P65 Activity and Pro-Inflammatory Cytokines. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[10]  P. Hu,et al.  Identification of genomic signatures in circulating tumor cells from breast cancer , 2015, International journal of cancer.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  S. Germain,et al.  Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer , 2014, Clinical Cancer Research.

[13]  S. Fan,et al.  Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma , 2014, Molecular Cancer.

[14]  E. Winer,et al.  Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Tsukamoto,et al.  ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis , 2014, Oncogene.

[16]  C. Duyckaerts,et al.  Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. , 2013, European heart journal.

[17]  M. de Boer,et al.  Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome , 2013, Breast Cancer Research and Treatment.

[18]  S. Germain,et al.  Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. , 2013, International journal of cardiology.

[19]  N. Erin,et al.  Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma , 2013, Breast Cancer Research and Treatment.

[20]  M. Moayeri,et al.  Anthrax Lethal Toxin Downregulates Claudin-5 Expression in Human Endothelial Tight Junctions , 2013, PloS one.

[21]  O. Chinot,et al.  Recent trends in epidemiology of brain metastases: an overview. , 2012, Anticancer research.

[22]  H. Zhang,et al.  Evaluation of TGFβ, XPO4, elF5A2 and ANGPTL4 as biomarkers in HCC , 2012, Experimental and therapeutic medicine.

[23]  R. Kreienberg,et al.  VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. , 2012, Gynecologic oncology.

[24]  Pengcheng Zhu,et al.  Emerging Roles of Angiopoietin-like 4 in Human Cancer , 2012, Molecular Cancer Research.

[25]  J. Bruix,et al.  Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[26]  G. Semenza,et al.  Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis , 2012, Journal of Molecular Medicine.

[27]  S. Germain,et al.  Protection against Myocardial Infarction and No-reflow through Preservation of Vascular Integrity by Angiopoietin-like 4 Running Title: Galaup Et Al.; Protecting Vascular Integrity in Heart Ischemia , 2022 .

[28]  J. L. Ding,et al.  ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. , 2011, Blood.

[29]  M. Caroli,et al.  Surgical Brain Metastases: Management and Outcome Related to Prognostic Indexes: A Critical Review of a Ten-Year Series , 2011, ISRN surgery.

[30]  G. Semenza,et al.  HIF-1-dependent Expression of Angiopoietin-like 4 and L1CAM Mediates Vascular Metastasis of Hypoxic Breast Cancer Cells to the Lungs , 2011, Oncogene.

[31]  R. Day,et al.  Proteolytic Processing of Angiopoietin-like Protein 4 by Proprotein Convertases Modulates Its Inhibitory Effects on Lipoprotein Lipase Activity* , 2011, The Journal of Biological Chemistry.

[32]  Dihua Yu,et al.  Microenvironment Determinants of Brain Metastasis , 2011, Cell & Bioscience.

[33]  T. Nagayasu,et al.  Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion. , 2010, Oncology reports.

[34]  M. Murawska,et al.  The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. , 2010, International journal of radiation oncology, biology, physics.

[35]  B. Leyland-Jones.  Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[37]  S. Ricard-Blum,et al.  Interaction of the coiled‐coil domain with glycosaminoglycans protects angiopoietin‐like 4 from proteolysis and regulates its antiangiogenic activity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  M. Milella,et al.  Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.

[39]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[40]  Pierre Corvol,et al.  Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness , 2006, Proceedings of the National Academy of Sciences.

[41]  N. Seidah,et al.  Evidence for proprotein convertase activity in the endoplasmic reticulum/early Golgi , 2005, FEBS letters.

[42]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[43]  Y. Masuho,et al.  Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. , 2003, Cancer research.

[44]  Thomas S. Reese,et al.  FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE , 1967, The Journal of cell biology.

[45]  M. Brightman,et al.  Morphology of blood-brain interfaces. , 1977, Experimental eye research.